Yamamoto Tsuneyuki, Une Teruaki
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Nihon Yakurigaku Zasshi. 2002 Sep;120(3):173-80. doi: 10.1254/fpj.120.173.
Animal models of psychiatric disorders are indispensable tools to gain insights into neural mechanisms underlying these disorders and to assess potential therapeutic actions of novel compounds in preclinical settings. However, it is difficult to establish appropriate animal models for these disorders because there is no proof on whether or not what occurs in the animal brain is comparable to what occurs in the human brain. The initial development of animal models of psychiatric disorders is often based on "face validity" as reflected in the similarity of behavioral signs and symptoms observed in humans and animal and subsequently based on "construct validity" as measured by strong correlation in behaviors and neural events between the animal model and patients of the disorder. The practical value of such animal models is reflected ultimately in their "predictive validity" in predicting the therapeutic efficacy of new treatments for psychiatric disorders. The present review will focus on animal models of schizophrenia and depression by the use of mainly environmental stress and pharmacological treatments, which are expected to induce signs and symptoms analogous to those of patients with such disorders.
精神疾病的动物模型是深入了解这些疾病潜在神经机制以及在临床前环境中评估新型化合物潜在治疗作用的不可或缺的工具。然而,由于无法证明动物大脑中发生的情况是否与人类大脑中发生的情况具有可比性,因此很难为这些疾病建立合适的动物模型。精神疾病动物模型的最初开发通常基于“表面效度”,这体现在人类和动物身上观察到的行为体征和症状的相似性,随后基于“结构效度”,通过动物模型与该疾病患者在行为和神经事件上的强相关性来衡量。此类动物模型的实际价值最终体现在它们在预测精神疾病新治疗方法的治疗效果方面的“预测效度”。本综述将主要通过环境应激和药物治疗来聚焦精神分裂症和抑郁症的动物模型,这些方法有望诱发与患有此类疾病的患者类似的体征和症状。